The reinstatement of Amgen with a Neutral rating by B of A Securities indicates that the firm sees the stock as fairly valued at current levels. The price target of $290 suggests that the firm believes there is potential for modest upside from the current price. This could have a neutral to slightly positive impact on the stock in the short term.